Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04678648 · ClinicalTrials.gov registry record · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
A Phase 1 study of Lung Cancer and Pancreatic Cancer, sponsored by RasCal Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 3
- Study locations
NCT04678648: Recruiting Phase 1 study of Lung Cancer and Pancreatic Cancer, sponsored by RasCal Therapeutics.
NCT04678648 is a Phase 1 study of Lung Cancer and Pancreatic Cancer that is actively recruiting participants, run by RasCal Therapeutics. The registered enrollment target is 134 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04678648, a Phase 1 study of Lung Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by RasCal Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 3
- Study locations
Study Summary
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Primary Outcome
The number and type of dose-limiting toxicities (DLTs) as defined in the protocol that occur during the first 21 days of treatment and maximum grade of all treatment-related events using CTCAE V5.0 will be used to identify a safe and tolerable dose.
Conditions Studied
Interventions
- DRUG RSC-1255 Dose Escalation
- DRUG RSC-1255 Dose Expansion
Study Locations (3)
California
- University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology - Los Angeles
Colorado
- Sarah Cannon, SCRI Oncology Partners - Health One - Denver
Tennessee
- Sarah Cannon, SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 1 |
What NCT04678648 shows while recruiting
NCT04678648 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (86% lower).
The record links to 6 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which RSC-1255 Dose Escalation is the first listed.
NCT04678648 reports a single indexed study location in California, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04678648 about?
NCT04678648 is a clinical study titled "A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies". RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The s...
What is the current status of trial NCT04678648?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2021-03-03. Estimated completion is 2027-01-30.
What conditions does trial NCT04678648 study?
This clinical trial studies the following conditions: Lung Cancer, Pancreatic Cancer, Glioblastoma, Advanced Malignant Solid Neoplasm, Colon Cancer.
What interventions are being tested in trial NCT04678648?
The interventions under investigation include: RSC-1255 Dose Escalation (DRUG), RSC-1255 Dose Expansion (DRUG).
Who is sponsoring clinical trial NCT04678648?
This trial is sponsored by RasCal Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04678648 being conducted?
This trial has 3 study locations across California, Colorado, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04678648's enrollment target sits among peer trials
134 158th of 409 higher than 251 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
- NCT05764720 · 134 participants · NA
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI